Treosulfan (Trecondi, Medac) in combination with fludarabine (generic) is indicated 'as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non-malignant diseases, and in paediatric patients older than 1 month with malignant diseases'.
This appraisal focuses on malignant diseases only.
The dosage schedule for treosulfan is available in the summary of product characteristics.
Treosulfan:
£494.40 per 5‑vial pack of 1 g powder for solution for injection (BNF online accessed December 2019)
£2,434.25 per 5‑vial pack of 5 g powder for solution for injection (BNF online accessed December 2019).
Fludarabine:
£155.00 per vial of 50 mg powder for solution for injection (BNF online accessed November 2019).